P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Subrata Ghosh; Millie Long; Elyssa Ott; Christopher Gasink; Thomas Baker; B. Goodwin; Ye Miao; Edward V. Loftus

doi:10.1093/ecco-jcc/jjac190.0683

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Subrata Ghosh
, Millie Long
, Elyssa Ott
, Christopher Gasink
, Thomas Baker
, B. Goodwin
, Ye Miao
, Edward V. Loftus

University of North Carolina at Chapel Hill
Janssen Scientific Affairs, LLC
Janssen Scientific Affairs, LLC
Mayo Clinic Rochester, MN

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Ustekinumab (UST) is an approved treatment for adults with inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]), psoriasis (PsO), and psoriatic arthritis (PsA). Here, we present pooled safety analyses in these approved indications of patients (pts) with active tuberculosis (TB) and opportunistic infections (OIs) through 5 years (yrs) of UST treatment.

Original language	English
Journal	Journal of Crohn's and Colitis
Volume	17
Issue number	1
DOIs	https://doi.org/10.1093/ecco-jcc/jjac190.0683
Publication status	Published - 30 Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Medicine
Ustekinumab
Concomitant
Internal medicine
Psoriatic arthritis
Bristol-Myers
Tuberculosis
Inflammatory bowel disease
Ulcerative colitis
Gastroenterology
Surgery
Adalimumab
Disease
Pathology

Access to Document

10.1093/ecco-jcc/jjac190.0683Licence: Unspecified

Cite this

@article{c29545d279b74139b05580803f11e6e0,

title = "P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications",

abstract = "Ustekinumab (UST) is an approved treatment for adults with inflammatory bowel disease (IBD: Crohn{\textquoteright}s disease [CD] and ulcerative colitis [UC]), psoriasis (PsO), and psoriatic arthritis (PsA). Here, we present pooled safety analyses in these approved indications of patients (pts) with active tuberculosis (TB) and opportunistic infections (OIs) through 5 years (yrs) of UST treatment.",

keywords = "Medicine, Ustekinumab, Concomitant, Internal medicine, Psoriatic arthritis, Bristol-Myers, Tuberculosis, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology, Surgery, Adalimumab, Disease, Pathology",

author = "Subrata Ghosh and Millie Long and Elyssa Ott and Christopher Gasink and Thomas Baker and B. Goodwin and Ye Miao and Loftus, \{Edward V.\}",

year = "2023",

month = jan,

day = "30",

doi = "10.1093/ecco-jcc/jjac190.0683",

language = "English",

volume = "17",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

AU - Ghosh, Subrata

AU - Long, Millie

AU - Ott, Elyssa

AU - Gasink, Christopher

AU - Baker, Thomas

AU - Goodwin, B.

AU - Miao, Ye

AU - Loftus, Edward V.

PY - 2023/1/30

Y1 - 2023/1/30

N2 - Ustekinumab (UST) is an approved treatment for adults with inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]), psoriasis (PsO), and psoriatic arthritis (PsA). Here, we present pooled safety analyses in these approved indications of patients (pts) with active tuberculosis (TB) and opportunistic infections (OIs) through 5 years (yrs) of UST treatment.

AB - Ustekinumab (UST) is an approved treatment for adults with inflammatory bowel disease (IBD: Crohn’s disease [CD] and ulcerative colitis [UC]), psoriasis (PsO), and psoriatic arthritis (PsA). Here, we present pooled safety analyses in these approved indications of patients (pts) with active tuberculosis (TB) and opportunistic infections (OIs) through 5 years (yrs) of UST treatment.

KW - Medicine

KW - Ustekinumab

KW - Concomitant

KW - Internal medicine

KW - Psoriatic arthritis

KW - Bristol-Myers

KW - Tuberculosis

KW - Inflammatory bowel disease

KW - Ulcerative colitis

KW - Gastroenterology

KW - Surgery

KW - Adalimumab

KW - Disease

KW - Pathology

UR - https://openalex.org/W4318578194

U2 - 10.1093/ecco-jcc/jjac190.0683

DO - 10.1093/ecco-jcc/jjac190.0683

M3 - Meeting abstract

SN - 1873-9946

VL - 17

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

IS - 1

ER -

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this